As an infectious diseases clinician who has managed patients with complicated monkeypox virus infections since 2018, I agree with Webb et al. that clinical management guidelines are helpful to those managing cases of monkeypox and welcome their efforts to identify potential gaps in available guidance. However, as the principal author for the original PHE guidance on monkeypox, I feel it is important to point out that the publicly available guidance for England was not intended to be detailed clinical guidance, which is likely why it was assigned such a low score in the systematic review by Webb et al.
Prior to 2022, clinical management of sporadic cases of mostly travel-associated monkeypox cases in England was the responsibility of five NHS England-commissioned Airborne HCID treatment centres. Readers of this systematic review may be under the false impression that, in the absence of published national clinical management guidance, those caring for cases in England had no access to advice or guidance, which is simply not the case. In addition to information shared through an active specialist peer-support network, not all guidance was published, and HCID treatment centres follow their own standardised protocols for HCID infection prevention and control, which are not published under the banner of 'monkeypox clinical guidance'. The case series describing the management of patients hospitalised with monkeypox in England between 2018 and 2021 (Adler H et al...
As an infectious diseases clinician who has managed patients with complicated monkeypox virus infections since 2018, I agree with Webb et al. that clinical management guidelines are helpful to those managing cases of monkeypox and welcome their efforts to identify potential gaps in available guidance. However, as the principal author for the original PHE guidance on monkeypox, I feel it is important to point out that the publicly available guidance for England was not intended to be detailed clinical guidance, which is likely why it was assigned such a low score in the systematic review by Webb et al.
Prior to 2022, clinical management of sporadic cases of mostly travel-associated monkeypox cases in England was the responsibility of five NHS England-commissioned Airborne HCID treatment centres. Readers of this systematic review may be under the false impression that, in the absence of published national clinical management guidance, those caring for cases in England had no access to advice or guidance, which is simply not the case. In addition to information shared through an active specialist peer-support network, not all guidance was published, and HCID treatment centres follow their own standardised protocols for HCID infection prevention and control, which are not published under the banner of 'monkeypox clinical guidance'. The case series describing the management of patients hospitalised with monkeypox in England between 2018 and 2021 (Adler H et al. Lancet Infectious Diseases, May 2022) suggests that there was no significant guidance void in England; in fact, that experience meant specialist hospitals in England were better prepared to care for hospitalised patients when the unprecedented outbreak began in May 2022, and various guidance documents - public facing and 'internal' were rapidly updated or produced to support clinicians working in a new outbreak context. Most importantly, and perhaps more useful that any written guidance, was the information sharing network for hospital physicians, which continues to meet to this day.
Guidance takes many different forms. Without understanding the scope, aims and target audience of publicly available guidance, it is inevitable that a systematic review will assign a low quality score when a piece of guidance never set out to be the comprehensive clinical guidance that the review is assessing; thus, one is effectively scoring the wrong thing.
While I welcome and am part of efforts to produce national and international clinical management guidelines for monkeypox, it is also clear that there is a not a single approach to managing patients, even hospitalised patients; clinical manifestations and the required and available treatment approaches will differ between countries and outbreaks. If a systematic review of clinical management guidelines for monkeypox is to be repeated, this is an important point to consider, along with ensuring the scope and aims of published guidance are fully appreciated in systematic reviews. For low-incidence emerging infections, it it also important to recognise that some countries may not publish all of their detailed guidance in a single document online.
Coming from an international relations background, I'm pleased to see more discussion of topics like this in global health, which were absent from my Global Health studies. Public health too often doesn't directly deal with power, though power is so central to health outcomes- positive and negative. I think our engagement with power imbalances is a big part of understanding power in public health, which includes seeking economic justice for marginalised groups.
Through a systematic review and meta-analysis, Dong et al (1) have calculated a global B. burgdorferi sensu lato (Bbsl) seroprevalence estimate of 14.5% (95% CI 12.8% to 16.3%). We question the accuracy and appropriateness of such an estimate.
As the authors demonstrate, seroprevalence estimates based on orthogonal 2-tier serological testing with a confirmatory Western-blot assay decrease the risk of false-positive results and are more reliable than those using single assays. Yet the pooled 14.5% estimate includes studies that used single assays, apparently without adjusting for the decreased reliability of single-tier testing. When studies using single-tier assays were excluded, the pooled estimate was reduced to 11.6% (95% CI 9.5% to 14.0%). The 14.5% estimate is based on studies spanning four population categories general, high-risk, tick-bitten and having Lyme-like symptoms. When these sub-groups were compared, the general population had a pooled seropositivity rate of 5.7% (95% CI 4.3% to 7.3%). We argue that only the general population category is relevant when estimating an unbiased population seroprevalence.
Irrespective of accuracy, using a headline global seroprevalence estimate may be misleading, implying homogeneity when, as the authors report, there is wide variation in B. burgdorferi seroprevalence between countries and regions. Furthermore, the authors suggest that analysis of seropositivity to anti-Bbsl antibodies enhances understanding of th...
Through a systematic review and meta-analysis, Dong et al (1) have calculated a global B. burgdorferi sensu lato (Bbsl) seroprevalence estimate of 14.5% (95% CI 12.8% to 16.3%). We question the accuracy and appropriateness of such an estimate.
As the authors demonstrate, seroprevalence estimates based on orthogonal 2-tier serological testing with a confirmatory Western-blot assay decrease the risk of false-positive results and are more reliable than those using single assays. Yet the pooled 14.5% estimate includes studies that used single assays, apparently without adjusting for the decreased reliability of single-tier testing. When studies using single-tier assays were excluded, the pooled estimate was reduced to 11.6% (95% CI 9.5% to 14.0%). The 14.5% estimate is based on studies spanning four population categories general, high-risk, tick-bitten and having Lyme-like symptoms. When these sub-groups were compared, the general population had a pooled seropositivity rate of 5.7% (95% CI 4.3% to 7.3%). We argue that only the general population category is relevant when estimating an unbiased population seroprevalence.
Irrespective of accuracy, using a headline global seroprevalence estimate may be misleading, implying homogeneity when, as the authors report, there is wide variation in B. burgdorferi seroprevalence between countries and regions. Furthermore, the authors suggest that analysis of seropositivity to anti-Bbsl antibodies enhances understanding of the global epidemiology of Lyme disease. Caution should be exercised here since Lyme disease as a clinical entity is only reliably described from temperate areas of the northern hemisphere, mirroring the distribution of its tick vectors (2). At least 20 species of bacteria belong to the Bbsl complex (2, 3) and could be transmitted to humans through a tick bite, but only a handful are pathogenic and cause Lyme disease (3). The serology assays used internationally to estimate borrelia exposure may recognise antibodies generated against non-pathogenic Bbsl species. Consequently, the Bbsl global seroprevalence estimate overestimates those who have experienced clinical Lyme disease (or asymptomatic infection) and may explain why Dong et al give Bbsl seroprevalence estimates for countries where no Lyme disease cases have been confirmed.
Dong et al derived a seroprevalence estimate for the UK in the 11-20% range based on two Scottish studies, with calculated seroprevalence estimates of 4.17% and 36.48% (4, 5). One (4) used Scottish blood donors. The other (5) utilised sera from individuals with suspected Lyme disease; it was not a study on either seroprevalence or incidence, was not representative of the general population and its inclusion introduces bias into the results. The true seroprevalence figure for Scotland is likely closer to the 4.2% estimate but importantly, there is regional variation (0 - 8.6%) within Scotland (4). Dong et al have used the biased Scottish estimate to extrapolate from one UK nation to others (England, Wales and Northern Ireland). This is misleading since published data on lab-confirmed Lyme disease cases show a higher incidence for Scotland than the other UK nations (6), although published seroprevalence data for the general populations in the other UK nations is lacking (6).
The study by Dong et al has been widely reported by media outlets leading to headlines claiming 1 in 7 people globally have been exposed to B. burgdorferi at some time (7). As described above, the interpretation of the ‘global’ seroprevalence estimate is flawed as are media releases based on it and may mislead and alarm the public unnecessarily. What is most important is that the public understand where high risk areas are locally and when travelling overseas, so that they can take appropriate measures to limit their exposure to ticks and to prevent Lyme and other tick-borne diseases.
References
1. Dong Y, Zhou G, Cao W, Xu X, Zhang Y, Ji Z, et al. Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis. BMJ Glob Health. 2022;7(6).
2. Mead PS. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2015;29(2):187-210.
3. Bobe JR, Jutras BL, Horn EJ, Embers ME, Bailey A, Moritz RL, et al. Recent Progress in Lyme Disease and Remaining Challenges. Front Med (Lausanne). 2021;8:666554.
4. Munro H, Mavin S, Duffy K, Evans R, Jarvis LM. Seroprevalence of lyme borreliosis in Scottish blood donors. Transfus Med. 2015;25(4):284-6.
5. Mavin S, Evans R, Milner RM, Chatterton JM, Ho-Yen DO. Local Borrelia burgdorferi sensu stricto and Borrelia afzelii strains in a single mixed antigen improves western blot sensitivity. J Clin Pathol. 2009;62(6):552-4.
6. Lorenc T, Jones-Diette J, Blanchard L, et al. Incidence and surveillance of Lyme disease: systematic review and policy mapping. London: EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London; 2017.
7. Wetzel C. More than 1 in 7 people worldwide have had Lyme disease. New Scientist. 2022.
The cases of human encephalitis by West Nile virus (WNV) recently diagnosed in northern Italy (Emilia Romagna and Veneto Regions), two of which occurred in elderly patients who experienced a fatal outcome (unpublished data), deserve special concern. This should apply, more in general, to the eco-epidemiology of all arthropod-borne infections, many of which are of zoonotic relevance. We are dealing, in fact, with a large group of viral (Zika virus, Dengue virus, Yellow Fever virus, Tick-Borne Encephalitis viruses, etc.), bacterial (Ehrlichia spp.) and protozoan (Plasmodium malariae, Leishmania spp., Trypanosoma spp., etc.) pathogens, a portion of whose life cycle takes place in an invertebrate host (insect or tick), from which the infectious agent, once acquired from an infected human or animal host, will be subsequently transferred to another susceptible, human or animal, host.
As far as WNV is specifically concerned, this zoonotic flaviviral pathogen showed up for the first time in Italy in 1998, thereby giving rise to a series of encephalomyelitis cases among horses from Tuscany Region (1).
Culex spp. mosquitoes - namely Culex pipiens - represent the main WNV vectors. Indeed, successful virus isolation has been obtained from Culex spp. mosquito pools recently sampled in Veneto Region (unpublished data).
Numerically speaking, arthropod-borne pathogens account for approximately two thirds of the biological noxae responsible for "e...
The cases of human encephalitis by West Nile virus (WNV) recently diagnosed in northern Italy (Emilia Romagna and Veneto Regions), two of which occurred in elderly patients who experienced a fatal outcome (unpublished data), deserve special concern. This should apply, more in general, to the eco-epidemiology of all arthropod-borne infections, many of which are of zoonotic relevance. We are dealing, in fact, with a large group of viral (Zika virus, Dengue virus, Yellow Fever virus, Tick-Borne Encephalitis viruses, etc.), bacterial (Ehrlichia spp.) and protozoan (Plasmodium malariae, Leishmania spp., Trypanosoma spp., etc.) pathogens, a portion of whose life cycle takes place in an invertebrate host (insect or tick), from which the infectious agent, once acquired from an infected human or animal host, will be subsequently transferred to another susceptible, human or animal, host.
As far as WNV is specifically concerned, this zoonotic flaviviral pathogen showed up for the first time in Italy in 1998, thereby giving rise to a series of encephalomyelitis cases among horses from Tuscany Region (1).
Culex spp. mosquitoes - namely Culex pipiens - represent the main WNV vectors. Indeed, successful virus isolation has been obtained from Culex spp. mosquito pools recently sampled in Veneto Region (unpublished data).
Numerically speaking, arthropod-borne pathogens account for approximately two thirds of the biological noxae responsible for "emerging infectious diseases", 70% of which would originate, in turn, from one or more animal reservoirs, as definitely proven with the two betacoronaviruses SARS-CoV and MERS-CoV, while being largely plausible and highly suspect also in the case of the pandemic SARS-CoV-2 betacoronavirus (2).
The seven years between 2015 and 2021 have been the hottest ones ever recorded on Earth within the last 140 years, with this significantly impacting also the vectorial efficiency of arthropods toward their respective pathogens. Indeed, under the present meteo-climatological conditions insects and ticks are now being increasingly reported to overcome the autumn and winter seasons ("overwintering") far more easily than in past decades. These progressively higher and higher average temperatures are responsible, in fact, for a (more or less) consistent reduction of the life cycle and replication ("extrinsic incubation period") of the infectious pathogens carried inside insects' and ticks' bodies. Based upon the above, a progressive "transfer to northern latitudes" of arthropod-borne infections, of either viral or non-viral aetiology, has been documented in more or less recent years, as clearly shown by the emergence of bluetongue virus - carried by Culicoides spp. - among ruminants from northern European Countries (3), as well as by the detection of Leishmania spp. - carried by Phlebotomus spp. - in dogs from UK (4).
In consideration of the above and, most importantly, in view of the documented zoonotic potential of many viral and non-viral, arthropod-borne pathogens (including WNV), a "One Health"-based and multidisciplinary approach would be absolutely needed for an "ad hoc" management of the complex ecology and epidemiology of the infections caused by such agents, with this reminding us (once again!) that human, animal and environmental health are mutually and inextricably linked to each other.
References
1) Cantile C, Di Guardo G, Eleni C, Arispici M. (2000). Clinical and neuropathological features of West Nile virus equine encephalomyelitis in Italy. Equine Veterinary Journal 32:31-35. doi: 10.2746/042516400777612080.
3) Carpenter S., Wilson A., Mellor P.S. (2009). Culicoides and the emergence of bluetongue virus in northern Europe. Trends in Microbiology 17:172-178. doi: 10.1016/j.tim.2009.01.001.
4) McKenna M., Attipa C., Tasker S., Augusto M. (2019). Leishmaniosis in a dog with no travel history outside of the UK. Veterinary Record 184:441. doi: 10.1136/vr.105157.
The article does not adequately take into account a crucial ethical and (by implication, legal) fact: the argument from proportionality does not justify arbitrary violations of the right to life or the removal of the right to free medical consent, for the following reasons.
Summary of the three strongest arguments against the ethical permissibility of vaccine mandates and why any medical procedure imposed by coercion must be refused.
1. Vaccine mandates imply that all humans are born in a defective, inherently harmful state that must be biotechnologically augmented to allow their unrestricted participation in society, and this constitutes discrimination on the basis of healthy, innate characteristics of the human race. (This point derives from my paper published here: https://jme.bmj.com/content/48/4/240).
2. Medical consent must be free – not coerced – in order to be valid. Any discrimination against the unvaccinated is economic or social opportunity coercion, precluding the possibility of valid medical consent. The right to free, uncoerced medical consent is not negotiable, under any circumstances, because without it we have no rights at all; every other right can be subverted by medical coercion. Crucially, by accepting any medical treatment imposed by coercion we would be acquiescing to the taking away of the right to free medical consent not just from ourselves but from our children and from futur...
The article does not adequately take into account a crucial ethical and (by implication, legal) fact: the argument from proportionality does not justify arbitrary violations of the right to life or the removal of the right to free medical consent, for the following reasons.
Summary of the three strongest arguments against the ethical permissibility of vaccine mandates and why any medical procedure imposed by coercion must be refused.
1. Vaccine mandates imply that all humans are born in a defective, inherently harmful state that must be biotechnologically augmented to allow their unrestricted participation in society, and this constitutes discrimination on the basis of healthy, innate characteristics of the human race. (This point derives from my paper published here: https://jme.bmj.com/content/48/4/240).
2. Medical consent must be free – not coerced – in order to be valid. Any discrimination against the unvaccinated is economic or social opportunity coercion, precluding the possibility of valid medical consent. The right to free, uncoerced medical consent is not negotiable, under any circumstances, because without it we have no rights at all; every other right can be subverted by medical coercion. Crucially, by accepting any medical treatment imposed by coercion we would be acquiescing to the taking away of the right to free medical consent not just from ourselves but from our children and from future generations, and we do not have the right to do this. Acquiescence to medical coercion is always unethical, even if the mandated intervention were a placebo.
3. Covid vaccines are known to occasionally cause deaths of healthy people. When an employee is required to receive Covid vaccination as a condition of employment, that employee is economically coerced to participate in an activity where some percentage of employees are expected to die ‘in the course of employment’ as a direct result of the mandated activity. This goes against the fundamental principles of medical ethics and workplace safety. It may be objected that Covid-19 also kills people, but these two categories of deaths are not ethically equivalent. Infection with SARS-CoV-2 is not mandated, whereas deaths resulting from mandatory vaccination are mandated deaths, a legalised killing of some people for the prospective benefit of the majority. Critically, any discrimination against the unvaccinated (or a privileged treatment of the vaccinated) amounts to a violation of the right to life, because a small percentage of the targeted population are expected to die as a result of this coercive treatment.
As the Australian economist Sanjeev Sabhlok said: “Governments are not authorised by law - by analogy - to burn down additional homes and kill unaffected people in order to save those who might be at risk of being engulfed in a bushfire.”
An earlier version of these arguments were formally submitted to the Inquiry into Public Health Amendment Bill 2021 (No 2) ACT, Australia:
It is with great interest that I read Doherty et al.’s commentary in which the authors express concern about the ethical appropriateness of a randomised controlled trial that had received ethical approval. Doherty et al.’s study serves as a valuable reminder that a study is not ethical simply because it has received ethical approval, as previous studies have also emphasised.1 One might also add that just because a study has reported having obtained ethical approval, it cannot be assumed that the study has adhered to the recommendations of the research ethics committee or informed the committee of its plans in full. Doshi (2020) reported on bioethicist Charles Wiejer’s concern that a randomised controlled trial of malaria vaccine Mosquirix had waived the requirement of informed consent.2 Weijer was quoted as saying “It is difficult to see how a research ethics committee could have approved a waiver of consent for the WHO malaria vaccine pilot cluster randomized trial.”2 These studies raise the question of whether academic journals should play a greater role in scrutinising the ethical appropriateness of studies submitted for publication?
As a doctoral student with a keen interest in public health ethics, I previously attended weekly editorial board meetings of a major scientific journal with the sole purpose of interrogating the submitted studies for ethical issues. In these meetings, I raised serious questions about some of the studies that had r...
It is with great interest that I read Doherty et al.’s commentary in which the authors express concern about the ethical appropriateness of a randomised controlled trial that had received ethical approval. Doherty et al.’s study serves as a valuable reminder that a study is not ethical simply because it has received ethical approval, as previous studies have also emphasised.1 One might also add that just because a study has reported having obtained ethical approval, it cannot be assumed that the study has adhered to the recommendations of the research ethics committee or informed the committee of its plans in full. Doshi (2020) reported on bioethicist Charles Wiejer’s concern that a randomised controlled trial of malaria vaccine Mosquirix had waived the requirement of informed consent.2 Weijer was quoted as saying “It is difficult to see how a research ethics committee could have approved a waiver of consent for the WHO malaria vaccine pilot cluster randomized trial.”2 These studies raise the question of whether academic journals should play a greater role in scrutinising the ethical appropriateness of studies submitted for publication?
As a doctoral student with a keen interest in public health ethics, I previously attended weekly editorial board meetings of a major scientific journal with the sole purpose of interrogating the submitted studies for ethical issues. In these meetings, I raised serious questions about some of the studies that had received ethical approval, which were typically met with shared concern. Whilst the editorial board had numerous scientific experts examining the study designs and methodologies, they did not have a dedicated ‘ethics expert’ responsible for appraising the ethical appropriateness of the submitted studies. The experience left me with doubt that the editorial team had the interest or capacity to proficiently identify ethical issues in the papers submitted for publication.
Doherty et al.’s commentary together with similar published concerns and my own experiences have left me wondering: is it time to explore the pros and cons of appointing ‘ethics experts’ to the editorial boards of peer-reviewed journals?
Yours sincerely,
Dr Robert Torrance
References:
1. Attarwala, H. TGN1412: From Discovery to Disaster. JYP 2010;2:332.
2. Doshi, P. WHO’s malaria vaccine study represents a “serious breach of international ethical standards.” BMJ 2020.368.
How to use heat stable carbetocin and tranexamic acid for postpartum haemorrhage in practice
A. Metin Gülmezoglu1, Sara Rushwan1
1 Concept Foundation, Geneva, Switzerland
We welcome the paper by Tran et al [1]. There are increasing number of options for postpartum haemorrhage (PPH) prevention and management as recommended by WHO and the context is important. We agree that at the national level the first step is to update the national policies including the guidelines and essential medicine lists (EMLs). Since 2019, Concept Foundation and its partners have been working in 14 East and West African sub-Saharan countries to facilitate those updates [2]. We are pleased to report that in 10 out of the 14 countries – Burkina Faso, DRC, Ethiopia, Ghana, Ivory Coast, Liberia, Rwanda, Sierra Leone, South Sudan, and Uganda – the national guideline and/or EML were updated during this period.
The strength of the project lies in the engagement with policy makers, Ministry of Health officials, clinicians, professional associations, and civil society organizations concurrently. However, competing national policy priorities such as COVID-19, timing of the previous updates, political instability and national capacity and leadership (or lack of) can make the updating process long and challenging even when there is an agreement to update. Secondly, even when the updates happen, proactive dissemination and training within the country can also take time. Thirdly, in the...
How to use heat stable carbetocin and tranexamic acid for postpartum haemorrhage in practice
A. Metin Gülmezoglu1, Sara Rushwan1
1 Concept Foundation, Geneva, Switzerland
We welcome the paper by Tran et al [1]. There are increasing number of options for postpartum haemorrhage (PPH) prevention and management as recommended by WHO and the context is important. We agree that at the national level the first step is to update the national policies including the guidelines and essential medicine lists (EMLs). Since 2019, Concept Foundation and its partners have been working in 14 East and West African sub-Saharan countries to facilitate those updates [2]. We are pleased to report that in 10 out of the 14 countries – Burkina Faso, DRC, Ethiopia, Ghana, Ivory Coast, Liberia, Rwanda, Sierra Leone, South Sudan, and Uganda – the national guideline and/or EML were updated during this period.
The strength of the project lies in the engagement with policy makers, Ministry of Health officials, clinicians, professional associations, and civil society organizations concurrently. However, competing national policy priorities such as COVID-19, timing of the previous updates, political instability and national capacity and leadership (or lack of) can make the updating process long and challenging even when there is an agreement to update. Secondly, even when the updates happen, proactive dissemination and training within the country can also take time. Thirdly, in the case of heat-stable carbetocin (HSC), even when policy updates are accomplished, the regulatory approval that is essential for the drug to enter the country can take time.
In 2021, we expanded our collaboration to include the International Federation of Gynecology and Obstetrics (FIGO) and International Confederation of Midwives (ICM) and their national counterparts to support the transition from policy updates to the development of clinical management protocols and job aids. FIGO and ICM developed a generic protocol on PPH prevention and treatment [3] and engagements with key national stakeholders were held to discuss its usability and adaptability to the country context, and how it could support existing country practices. So far, Ethiopia, Ghana, Rwanda, and Uganda have developed a national PPH clinical protocol that has been approved by the Ministry of Health, and these countries will develop supporting job aids. This work is planned to be completed in 4 other countries – Burkina Faso, Liberia, Sierra Leone, and South Sudan.
The main determinant of choosing which drug(s) to use should be the presence of a skilled birth attendant and reliable cold chain and storage. The more established injectable uterotonics must be kept in cold chain and storage, and quality-assured products must be prioritized for procurement. Implementation considerations must include ensuring that staff know and adhere to the fact that HSC is contraindicated for labour induction and augmentation. HSC is often used for PPH treatment, but this is off-label and the benefits and potential harms are uncertain. Both HSC and tranexamic acid (TXA) should be considered for implementation in peripheral and referral levels of the health care system since at peripheral level the cold chain issues are likely to be more prevalent and the lifesaving role of a quality-assured uterotonic and timely administered TXA in cases of haemorrhage is likely to be crucial. The fact that there seems to be support for intramuscular administration for TXA will make implementation at the periphery easier [4]. In referral settings with surgical capacity, it is essential that TXA is kept in a place where accidental mix-up with local anesthetics that are used in intrathecal anesthesia is avoided, since there have been case reports of deaths due to accidental TXA administration into the intrathecal space [5,6].
We also agree that HSC and TXA should be carefully integrated into the health system in an enabling environment and considering the context perspectives mentioned above. Concept Foundation will conduct implementation pilots in Burkina Faso, Ethiopia, Ghana, Sierra Leone, and Uganda to assess appropriate use following training of healthcare providers, and integration of the two medicines into routine PPH care management. The results of this research will be useful in better understanding the enablers and barriers for successful introduction of essential PPH medicines into clinical practice.
Our experience demonstrates that there are several barriers to access essential, heat-stable PPH medicines that require operationalization of end-to-end thinking at the national level. By end-to-end thinking, we mean addressing the challenges from the highest national policy level right down to the practicing care provider in the most peripheral level of health care where childbirth takes place. To date, most existing programs have focused either on policy level change or health care provider behavior change. Our project adopts a holistic approach, that seeks to align normative change, clinical protocol development, pilot implementation, procurement, and product introduction.
Progress in our project presents a great opportunity to allow the objectives and approach to be achieved in most high-burden countries with modest resources. However, there is undoubtedly a greater need for investment in advocacy, training, and dissemination tools to support the implementation of national guidelines in a locally appropriate way, while ensuring the WHO recommendations are reflected accurately.
References:
[1] Tran NT, Schulte-Hillen C, et al. How to use heat-stable carbetocin and tranexamic acid for the prevention and treatment of postpartum haemorrhage in low-resource settings. BMJ Global Health. 2022; 7:e008913.
[2] Concept Foundation, Country Support page. Geneva; 2021. https://www.conceptfoundation.org/what-we-do/country-support/. Accessed April 28, 2022.
[3] International Federation of Gynecology and Obstetrics (FIGO), Current FIGO projects, IAP page, Project Resources. London; 2022. https://www.figo.org/improving-access-essential-medicines-reduce-postpar.... Accessed April 29, 2022.
[4] Arribas M, Roberts I, et al. WOMAN-PharmacoTXA trial: Study
protocol for a randomised controlled trial to assess the pharmacokinetics and
pharmacodynamics of intramuscular, intravenous and oral administration of
tranexamic acid in women giving birth by caesarean section. Wellcome Open Res. 2021; 6:157.
[5] Patel S, Robertson B, et al. Catastrophic drug errors involving tranexamic acid administered during spinal anaesthesia. Anaesthesia. 2019; 74: 904-914.
[6] Palanisamy A, Kinsella SM. Spinal tranexamic acid – a new killer in town. Anaesthesia. 2019; 74: 831-833.
The activities in this narrative were supported by funding from MSD, through its MSD for Mothers initiative and are the sole responsibility of the authors. MSD for Mothers is an initiative of Merck & Co., Inc., Rahway, NJ, USA
It is a humble request if you could kindly specify the names of villages and areas that you surveyed, as it would be of immense help and guidance.
Thank you
I am extremely puzzled by the lack of any response regarding my proposed comments regarding this article. I've submitted my comments twice, but they have not been published. I cannot imagine why. It appears to be a discretionary censorship, which is of course contrary to BMJ's published editorial policies which generally favor respectful discourse. I would greatly appreciate an explanation and an appeal to a larger panel of BMJ editors.
To repeat...for the third time,... regarding this article:
There is a growing interest in developing evidenced based standards for public health policy initiatives.[1] In response to this effort, Burris et al have put forward their own initial effort to identify the potential effects of laws regulating abortion on women’s health.[2] Unfortunately, they apparently failed to include in their research team anyone with familiarity with the literature regarding the negative physical and psychological effects of coerced and unnecessary abortions. This is not a minor oversight.
Regarding the issue of women’s autonomy, increasing legal access to abortion is a double-edged sword. Easier access makes it easier for women to choose abortion for their own self-interests, but it also makes it easier for those pressuring women into unwanted abortions to abuse women’s rights.[3]
Coerced abortions are especially common among women enslaved in sex trafficking.[4,5] But it is also common within...
I am extremely puzzled by the lack of any response regarding my proposed comments regarding this article. I've submitted my comments twice, but they have not been published. I cannot imagine why. It appears to be a discretionary censorship, which is of course contrary to BMJ's published editorial policies which generally favor respectful discourse. I would greatly appreciate an explanation and an appeal to a larger panel of BMJ editors.
To repeat...for the third time,... regarding this article:
There is a growing interest in developing evidenced based standards for public health policy initiatives.[1] In response to this effort, Burris et al have put forward their own initial effort to identify the potential effects of laws regulating abortion on women’s health.[2] Unfortunately, they apparently failed to include in their research team anyone with familiarity with the literature regarding the negative physical and psychological effects of coerced and unnecessary abortions. This is not a minor oversight.
Regarding the issue of women’s autonomy, increasing legal access to abortion is a double-edged sword. Easier access makes it easier for women to choose abortion for their own self-interests, but it also makes it easier for those pressuring women into unwanted abortions to abuse women’s rights.[3]
Coerced abortions are especially common among women enslaved in sex trafficking.[4,5] But it is also common within households precisely because every pregnancy impacts not just the pregnant woman, but also male partners, parents, employers, and society at large . . . as evidenced by advocates of population control who have sought and implemented public policies that discourage birth.[3]
As many as 64% of American women acknowledging a history of abortion report having felt pressured to abort by others.[6] Similarly, a 2021 study of women seeking abortion found that only 42% described their pregnancy as never wanted.[7] The pressure to abort a pregnancy that might otherwise be welcomed typically comes from their male partners, parents, employers and social services officials.[8]
As might be imagined, negative psychological reactions to abortion are more common when women feel pressured into an abortion or have other conflicting maternal interests and moral beliefs.[6,9] These are just a few of the 15 risk factors identified by the APA for negative psychological reactions. They include: terminating a pregnancy that is wanted or meaningful; perceived pressure from others to terminate a pregnancy; perceived opposition to the abortion from partners, family, and/or friends; lack of perceived social support from others; various personality traits (e.g., low self-esteem, a pessimistic outlook, low-perceived control over life); a history of mental health problems prior to the pregnancy; feelings of stigma; perceived need for secrecy; exposure to antiabortion picketing; use of avoidance and denial coping strategies; feelings of commitment to the pregnancy; ambivalence about the abortion decision; low perceived ability to cope with the abortion; history of prior abortion; and late term abortion.[9] The best evidence indicates that the vast majority of women undergoing abortion have one or more of these risk factors.[9]
Even assuming that the negative psychological associated with abortion, including increased risk of substance abuse,[9] postpartum psychiatric risks,[10] sleep disorders,[11] posttraumatic stress disorder,[9] and suicidal ideation and other risk taking behaviors[9] are entirely due to coerced and unwanted abortions, the importance of laws intended to prevent unwanted abortions should not be ignored…but that is precisely what Burris et al have done.
For example, one of the reasons for laws requiring parental involvement or notification are to help prevent a minor from undergoing a coerced abortion at the behest of the male partner or his family. They are also intended to prevent a minor from fearfully consenting to an otherwise unwanted or unnecessary abortion because of a mistaken fear that the minor’s parents will reject her because of her sexual activity and will not support her desire to keep the pregnancy.
But in Table 1, the benefit of “prevention of unwanted, unnecessary or unsafe legal abortions” is not identified in the list of “plausibly related outcomes” for any of the types of laws considered. Nor is there any consideration of “saved costs” and in regard to fewer treatments for the negative health effects associated with unwanted abortion.[9]
Numerous studies have also found a strong link between induced abortion and subsequent pre-mature and low-birth weight deliveries.[12] In the context of the United States, the increased medical costs in treating subsequently pre-maturely born children just to the point of hospital discharge apportions out to approximately $100,000 per 100,000 abortions. Therefore, any reduction in abortion rates that may result from laws that reduce the risk of coerced and unwanted abortions would produce significant health care savings, would reduce the risk of lifelong health complications associated with premature and low birth weight deliveries, and would save numerous lives among later planned pregnancies. But again, none of these benefits appear in Table 1.
Moreover, literally every record linkage study (eleven in total) examining reproductive outcomes associated with mortality has shown that abortion is associated with an increased risk of premature death among women exposed to abortion.[13] There is even a dose effect, with each abortion increasing the risk of an early death by approximately 50 percent.[13] At least a part of this increased risk is due to the increased risk of within a year of an abortion.[14,15] But even if we again assume that all these risks attach only to unwanted abortions (presuming that if a woman truly wants an abortion according to her own guiding lights, she will experience no psychological harm), the fact remains that any law which may help to reduce the rate of unwanted abortions is likely to reduce mortality rates and thereby increase work productivity and gross national product. But, yet again, the positive plausible outcomes have been omitted from Table 1
Notably, “unintended childbirth” is one plausible outcome that Burris et al have associated with every type of law identified in Table 1. But that outcome is poorly defined. When, and how often, is “unintended childbirth” a benefit to women and when is it a harm? Countless women report great satisfaction and blessing from their subsequent delivery of unplanned pregnancies. In fact, the Turnaway Study found that among all the women who were denied a late term abortion, 60% reported being happy about continuing their pregnancies, and by the time the child was born, only 12% still wished they could have had the abortion.[16] The bottom line is that many “unintended” and even “unwanted” pregnancies are associated with a mix of feelings, a mix that in the long run often result in a “welcomed” child, one that is valued not because the child was planned but simply it is the woman’s and her family’s child. Given that Burris et al are arguing for better research to support policy decisions, the importance of better research to identify when and how often unintended pregnancies result in a welcomed child should be a priority, as well as research to identify public policies that can help to make it easier for families to welcome unintended children.
Finally, Burris et al have failed to identify in the list of potential legal interventions laws governing informed consent, risk disclosure and pre-abortion screening for risk factors identifying women who may be at greater risk of being coerced or may feel pressured by social circumstance to agree to an abortion contrary to their moral beliefs and/or maternal desired.
In short, Burris et al’s analysis has failed to fully describe or analyze the plausible effects of statutes and public policies intended to protect women from unwanted, unnecessary and unsafe legal abortions. Simply declaring abortion legal does not necessarily render them safe and effective for all women in any and all circumstances of an “unintended” pregnancy.
Unfortunately, “unintended” pregnancies are often more unwanted by others (including population control activists) than they are by the pregnant themselves. In many cases, women are resiliently willing to embrace their unintended pregnancies as a welcomed-children. Often, it is only the hostility of others, and the accompanying pressure to submit to unwanted abortions, that is the true attack on women’s rights and autonomy.
Laws designed to identify and alleviate the pressures on women to undergo unwanted and unnecessary abortion should be pursued and implemented to save lives, reduce costs, and increase the well-being of both women and their children.
Competing Interest
David Reardon is the Director the Elliot Institute which sponsors peer reviewed medical research, promotes post-abortion healing programs, and advocates for laws requiring pre-abortion screening for coercion and other risk factors associated with negative outcomes for women.
References
1. Rehfuess EA, Stratil JM, Scheel IB, Portela A, Norris SL, Baltussen R. The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective. BMJ Glob Heal [Internet]. 2019 Jan 1 [cited 2022 Jan 13];4(Suppl 1):e000844. Available from: https://gh.bmj.com/content/4/Suppl_1/e000844
2. Burris S, Ghorashi AR, Cloud LF, Rebouché R, Skuster P, Lavelanet A. Identifying data for the empirical assessment of law (IDEAL): A realist approach to research gaps on the health effects of abortion law. BMJ Glob Heal [Internet]. 2021 Jun 1 [cited 2022 Jan 13];6(6):e005120. Available from: https://gh.bmj.com/content/6/6/e005120
3. Reardon DC. Abortion decisions and the duty to screen: clinical, ethical, and legal implications of predictive risk factors of post-abortion maladjustment. J Contemp Health Law Policy. 2003;20(1):33–114.
4. Coyle C. Sex Trafficking. In: MacNair RM, editor. Peace Psychology Perspectives on Abortion. Kansas City. MO: Feminism & Nonviolence Studies Association; 2016.
5. Lederer L, Wetzel C. The Health Consequences of Sex Trafficking and Their Implications for Identifying Victims in Healthcare Facilities. Ann Heal Law. 2014;23(1):61.
6. Rue VM, Coleman PK, Rue JJ, Reardon DC. Induced abortion and traumatic stress: A preliminary comparison of American and Russian women. Med Sci Monit. 2004;10(10):SR5–16.
7. Biggs MA, Neilands TB, Kaller S, Wingo E, Ralph LJ. Developing and validating the Psychosocial Burden among people Seeking Abortion Scale (PB-SAS). Vaingankar JA, editor. PLoS One [Internet]. 2020 Dec 10 [cited 2021 Feb 8];15(12 December):e0242463. Available from: https://dx.plos.org/10.1371/journal.pone.0242463
8. Elliot Institute. Forced Abortion in America: A Special Report [Internet]. Springfield IL; 2004. Available from: https://afterabortion.org/new-elliot-institute-report-exposed-americas-f...
9. Reardon DC. The abortion and mental health controversy: A comprehensive literature review of common ground agreements, disagreements, actionable recommendations, and research opportunities. SAGE Open Med [Internet]. 2018;6:205031211880762. Available from: http://journals.sagepub.com/doi/10.1177/2050312118807624
10. Reardon DC, Craver C. Effects of pregnancy loss on subsequent postpartum mental health: A prospective longitudinal cohort study. Int J Environ Res Public Health [Internet]. 2021 Feb 2 [cited 2021 Mar 17];18(4):1–11. Available from: https://pubmed.ncbi.nlm.nih.gov/33672236/
11. Reardon DC, Coleman PK. Relative treatment rates for sleep disorders and sleep disturbances following abortion and childbirth: a prospective record-based study. Sleep. 2006;29(1):105–6.
12. Calhoun BC, Shadigian E, Rooney B. Cost consequences of induced abortion as an attributable risk for preterm birth and impact on informed consent. J Reprod Med. 2007;52(10):929–37.
13. Reardon DC, Thorp JM. Pregnancy associated death in record linkage studies relative to delivery, termination of pregnancy, and natural losses: A systematic review with a narrative synthesis and meta-analysis. SAGE Open Med [Internet]. 2017 Dec 13 [cited 2018 Aug 15];5:205031211774049. Available from: http://journals.sagepub.com/doi/10.1177/2050312117740490
14. Gissler M, Berg C, Bouvier-Colle M-H, Buekens P. Injury deaths, suicides and homicides associated with pregnancy, Finland 1987-2000. Eur J Public Health. 2005 Oct;15(5):459–63.
15. Reardon D, Strahan T, Thorp … J. Deaths Associated with Abortion Compared to Childbirth-A Review of New and Old Data and the Medical and Legal Implications [Internet]. J. Contemp. Health …. 2003. Available from: http://heinonlinebackup.com/hol-cgi-bin/get_pdf.cgi?handle=hein.journals...
16. Foster DG. The Turnaway Study: ten years, a thousand women, and the consequences of having--or being denied--an abortion. New York, NY: Scribner; 2020. p. 360.
Dear sir,
We herewith report effects of disruptions on maternal and child health services in Maharashtra, India.
Covid 19- collateral damage on nutrition of women and children, in Maharashtra, India
Phadke M1,Nair R2,Menon P3,Jotkar R4, Saunik S5
India has been battling the Covid 19 pandemic like most other countries of the world. The first two waves, particularly the second wave produced devastating effects on many aspects of human health and welfare .Disease mortality and morbidity was unparalleled. In addition to these direct effects of Covid 19 disease itself, a number of indirect effects of Covid 19 on women, adolescent girls and children occurred. Lockdowns, loss of jobs, decrease in salaries, migration, supply chain disruption, inadequacy and inaccessibility of foods, green vegetables, stoppage of midday meals due to school closures, inadequate distribution of iron folic acid tablets from anganwadis impacted women and children’s nutrition.
Disruptions in maternal health services have been reported 1. We report two observations on occurrence of Neural tube defects and severe acute malnutrition in children during the years from 1st January to 31st December of 2020 and 2021. A team of doctors under the national health program of RBSK(Rashtriya Bal Swasthya Karyakram), examined children for '4Ds' i.e. Defects at birth, Diseases in children, Deficiency conditions and Developmental delays including disabilities. The year...
Dear sir,
We herewith report effects of disruptions on maternal and child health services in Maharashtra, India.
Covid 19- collateral damage on nutrition of women and children, in Maharashtra, India
Phadke M1,Nair R2,Menon P3,Jotkar R4, Saunik S5
India has been battling the Covid 19 pandemic like most other countries of the world. The first two waves, particularly the second wave produced devastating effects on many aspects of human health and welfare .Disease mortality and morbidity was unparalleled. In addition to these direct effects of Covid 19 disease itself, a number of indirect effects of Covid 19 on women, adolescent girls and children occurred. Lockdowns, loss of jobs, decrease in salaries, migration, supply chain disruption, inadequacy and inaccessibility of foods, green vegetables, stoppage of midday meals due to school closures, inadequate distribution of iron folic acid tablets from anganwadis impacted women and children’s nutrition.
Disruptions in maternal health services have been reported 1. We report two observations on occurrence of Neural tube defects and severe acute malnutrition in children during the years from 1st January to 31st December of 2020 and 2021. A team of doctors under the national health program of RBSK(Rashtriya Bal Swasthya Karyakram), examined children for '4Ds' i.e. Defects at birth, Diseases in children, Deficiency conditions and Developmental delays including disabilities. The year 2020 was a reflection of health and nutrition status of adolescent girls, who were married in the pre-Covid years and delivered babies in the year 2020 and children in precovid time. The year 2021 reflected the health and nutrition status of women in the Covid year of 2020 . It also reflected the status of nutrition in children in 2020 i.e. precovid times and 2021 reflecting nutritional insult in 2020.
2121564 children were examined in 2020. 112(0.005%) were detected to have neural tube defects ( NTDs). In 2021, 101(0.02%) had neural tube defects in 516655 babies which are four times that of 2020.(p<0.001). The number of babies born with NTDs were probably affected by Covid induced collateral nutrition insult i.e. folic acid deficiency in women during periconceptional period. Severe acute malnutrition was detected by measuring weight for height below -3SD on WHO growth charts. 7482 children had SAM (0.353%) in 2020 and 7148 (1.38%) children had SAM in 2021. (p<0.001).
Occurrence of SAM is a measure of acute nutritional insult to children . Inadequate nutrition in 2020 manifested in more children developing SAM and the number is four times more than previous year.
We declare no conflict of interest.
1. Sr. Adv, Ex-VC MUHS, Mumbai,
2. Nutrition Specialist, UNICEF, Mumbai,
3. Assoc. Prof, Ped and Med Edu, DYP. Med college, Pune,
4. Sr. Consultant, Pub.health, RJNM,Mumbai,
5. Addl Chief Sec. Govt of Mah,Mumbai, India.
References
1.Zeus Aranda, Thierry Binda, Katherine Tashman,Ananya Tadikon Daniel Maweu,Emma Jean Boley6,Isaac Mphande, Isata Dumbuya, Mariana Montaño, Mary Clisbee, Mc Geofrey Mvula,
Melino Ndayizigiye Meredith Casella Jean-Baptiste, Prince F Varney,Sarah Anyango Karen Ann GrépiJean Bethany Hedt-Gauthier, Isabel R Fulcher on behalf of the Cross-site COVID-19 Syndromic Surveillance Working Group. Disruptions in maternal health service use during the COVID-19 pandemic in 2020: BMJ Global Health 2021 Vol7 issue1http://dx.doi.org/10.1136/bmjgh-2021-007247)
As an infectious diseases clinician who has managed patients with complicated monkeypox virus infections since 2018, I agree with Webb et al. that clinical management guidelines are helpful to those managing cases of monkeypox and welcome their efforts to identify potential gaps in available guidance. However, as the principal author for the original PHE guidance on monkeypox, I feel it is important to point out that the publicly available guidance for England was not intended to be detailed clinical guidance, which is likely why it was assigned such a low score in the systematic review by Webb et al.
Prior to 2022, clinical management of sporadic cases of mostly travel-associated monkeypox cases in England was the responsibility of five NHS England-commissioned Airborne HCID treatment centres. Readers of this systematic review may be under the false impression that, in the absence of published national clinical management guidance, those caring for cases in England had no access to advice or guidance, which is simply not the case. In addition to information shared through an active specialist peer-support network, not all guidance was published, and HCID treatment centres follow their own standardised protocols for HCID infection prevention and control, which are not published under the banner of 'monkeypox clinical guidance'. The case series describing the management of patients hospitalised with monkeypox in England between 2018 and 2021 (Adler H et al...
Show MoreComing from an international relations background, I'm pleased to see more discussion of topics like this in global health, which were absent from my Global Health studies. Public health too often doesn't directly deal with power, though power is so central to health outcomes- positive and negative. I think our engagement with power imbalances is a big part of understanding power in public health, which includes seeking economic justice for marginalised groups.
Through a systematic review and meta-analysis, Dong et al (1) have calculated a global B. burgdorferi sensu lato (Bbsl) seroprevalence estimate of 14.5% (95% CI 12.8% to 16.3%). We question the accuracy and appropriateness of such an estimate.
As the authors demonstrate, seroprevalence estimates based on orthogonal 2-tier serological testing with a confirmatory Western-blot assay decrease the risk of false-positive results and are more reliable than those using single assays. Yet the pooled 14.5% estimate includes studies that used single assays, apparently without adjusting for the decreased reliability of single-tier testing. When studies using single-tier assays were excluded, the pooled estimate was reduced to 11.6% (95% CI 9.5% to 14.0%). The 14.5% estimate is based on studies spanning four population categories general, high-risk, tick-bitten and having Lyme-like symptoms. When these sub-groups were compared, the general population had a pooled seropositivity rate of 5.7% (95% CI 4.3% to 7.3%). We argue that only the general population category is relevant when estimating an unbiased population seroprevalence.
Irrespective of accuracy, using a headline global seroprevalence estimate may be misleading, implying homogeneity when, as the authors report, there is wide variation in B. burgdorferi seroprevalence between countries and regions. Furthermore, the authors suggest that analysis of seropositivity to anti-Bbsl antibodies enhances understanding of th...
Show MoreDear Editor,
The cases of human encephalitis by West Nile virus (WNV) recently diagnosed in northern Italy (Emilia Romagna and Veneto Regions), two of which occurred in elderly patients who experienced a fatal outcome (unpublished data), deserve special concern. This should apply, more in general, to the eco-epidemiology of all arthropod-borne infections, many of which are of zoonotic relevance. We are dealing, in fact, with a large group of viral (Zika virus, Dengue virus, Yellow Fever virus, Tick-Borne Encephalitis viruses, etc.), bacterial (Ehrlichia spp.) and protozoan (Plasmodium malariae, Leishmania spp., Trypanosoma spp., etc.) pathogens, a portion of whose life cycle takes place in an invertebrate host (insect or tick), from which the infectious agent, once acquired from an infected human or animal host, will be subsequently transferred to another susceptible, human or animal, host.
Show MoreAs far as WNV is specifically concerned, this zoonotic flaviviral pathogen showed up for the first time in Italy in 1998, thereby giving rise to a series of encephalomyelitis cases among horses from Tuscany Region (1).
Culex spp. mosquitoes - namely Culex pipiens - represent the main WNV vectors. Indeed, successful virus isolation has been obtained from Culex spp. mosquito pools recently sampled in Veneto Region (unpublished data).
Numerically speaking, arthropod-borne pathogens account for approximately two thirds of the biological noxae responsible for "e...
The article does not adequately take into account a crucial ethical and (by implication, legal) fact: the argument from proportionality does not justify arbitrary violations of the right to life or the removal of the right to free medical consent, for the following reasons.
Summary of the three strongest arguments against the ethical permissibility of vaccine mandates and why any medical procedure imposed by coercion must be refused.
1. Vaccine mandates imply that all humans are born in a defective, inherently harmful state that must be biotechnologically augmented to allow their unrestricted participation in society, and this constitutes discrimination on the basis of healthy, innate characteristics of the human race. (This point derives from my paper published here: https://jme.bmj.com/content/48/4/240).
2. Medical consent must be free – not coerced – in order to be valid. Any discrimination against the unvaccinated is economic or social opportunity coercion, precluding the possibility of valid medical consent. The right to free, uncoerced medical consent is not negotiable, under any circumstances, because without it we have no rights at all; every other right can be subverted by medical coercion. Crucially, by accepting any medical treatment imposed by coercion we would be acquiescing to the taking away of the right to free medical consent not just from ourselves but from our children and from futur...
Show MoreDear Editor,
It is with great interest that I read Doherty et al.’s commentary in which the authors express concern about the ethical appropriateness of a randomised controlled trial that had received ethical approval. Doherty et al.’s study serves as a valuable reminder that a study is not ethical simply because it has received ethical approval, as previous studies have also emphasised.1 One might also add that just because a study has reported having obtained ethical approval, it cannot be assumed that the study has adhered to the recommendations of the research ethics committee or informed the committee of its plans in full. Doshi (2020) reported on bioethicist Charles Wiejer’s concern that a randomised controlled trial of malaria vaccine Mosquirix had waived the requirement of informed consent.2 Weijer was quoted as saying “It is difficult to see how a research ethics committee could have approved a waiver of consent for the WHO malaria vaccine pilot cluster randomized trial.”2 These studies raise the question of whether academic journals should play a greater role in scrutinising the ethical appropriateness of studies submitted for publication?
As a doctoral student with a keen interest in public health ethics, I previously attended weekly editorial board meetings of a major scientific journal with the sole purpose of interrogating the submitted studies for ethical issues. In these meetings, I raised serious questions about some of the studies that had r...
Show MoreHow to use heat stable carbetocin and tranexamic acid for postpartum haemorrhage in practice
A. Metin Gülmezoglu1, Sara Rushwan1
Show More1 Concept Foundation, Geneva, Switzerland
We welcome the paper by Tran et al [1]. There are increasing number of options for postpartum haemorrhage (PPH) prevention and management as recommended by WHO and the context is important. We agree that at the national level the first step is to update the national policies including the guidelines and essential medicine lists (EMLs). Since 2019, Concept Foundation and its partners have been working in 14 East and West African sub-Saharan countries to facilitate those updates [2]. We are pleased to report that in 10 out of the 14 countries – Burkina Faso, DRC, Ethiopia, Ghana, Ivory Coast, Liberia, Rwanda, Sierra Leone, South Sudan, and Uganda – the national guideline and/or EML were updated during this period.
The strength of the project lies in the engagement with policy makers, Ministry of Health officials, clinicians, professional associations, and civil society organizations concurrently. However, competing national policy priorities such as COVID-19, timing of the previous updates, political instability and national capacity and leadership (or lack of) can make the updating process long and challenging even when there is an agreement to update. Secondly, even when the updates happen, proactive dissemination and training within the country can also take time. Thirdly, in the...
It is a humble request if you could kindly specify the names of villages and areas that you surveyed, as it would be of immense help and guidance.
Thank you
Dear Editor,
I am extremely puzzled by the lack of any response regarding my proposed comments regarding this article. I've submitted my comments twice, but they have not been published. I cannot imagine why. It appears to be a discretionary censorship, which is of course contrary to BMJ's published editorial policies which generally favor respectful discourse. I would greatly appreciate an explanation and an appeal to a larger panel of BMJ editors.
To repeat...for the third time,... regarding this article:
There is a growing interest in developing evidenced based standards for public health policy initiatives.[1] In response to this effort, Burris et al have put forward their own initial effort to identify the potential effects of laws regulating abortion on women’s health.[2] Unfortunately, they apparently failed to include in their research team anyone with familiarity with the literature regarding the negative physical and psychological effects of coerced and unnecessary abortions. This is not a minor oversight.
Regarding the issue of women’s autonomy, increasing legal access to abortion is a double-edged sword. Easier access makes it easier for women to choose abortion for their own self-interests, but it also makes it easier for those pressuring women into unwanted abortions to abuse women’s rights.[3]
Coerced abortions are especially common among women enslaved in sex trafficking.[4,5] But it is also common within...
Show MoreDear sir,
We herewith report effects of disruptions on maternal and child health services in Maharashtra, India.
Covid 19- collateral damage on nutrition of women and children, in Maharashtra, India
Phadke M1,Nair R2,Menon P3,Jotkar R4, Saunik S5
India has been battling the Covid 19 pandemic like most other countries of the world. The first two waves, particularly the second wave produced devastating effects on many aspects of human health and welfare .Disease mortality and morbidity was unparalleled. In addition to these direct effects of Covid 19 disease itself, a number of indirect effects of Covid 19 on women, adolescent girls and children occurred. Lockdowns, loss of jobs, decrease in salaries, migration, supply chain disruption, inadequacy and inaccessibility of foods, green vegetables, stoppage of midday meals due to school closures, inadequate distribution of iron folic acid tablets from anganwadis impacted women and children’s nutrition.
Show MoreDisruptions in maternal health services have been reported 1. We report two observations on occurrence of Neural tube defects and severe acute malnutrition in children during the years from 1st January to 31st December of 2020 and 2021. A team of doctors under the national health program of RBSK(Rashtriya Bal Swasthya Karyakram), examined children for '4Ds' i.e. Defects at birth, Diseases in children, Deficiency conditions and Developmental delays including disabilities. The year...
Pages